Real world data show therapy discontinuation is feasible in chronic hepatitis B

It is feasible for patients with negative HBV e-antigen chronic hepatitis B to discontinue nucleos(t)ide analogues therapy with low quantitative hepatitis B surface antigen levels, per a presentation at The Liver Meeting Digital Experience.“Severe ALT flare can occur even if you have low surface antigen levels at the time of stopping, which means we need to follow all those patients who stop treatment very closely and this recommended in our guidelines,” Hassan Azhari, MD, from the department of gastroenterology and hepatology at the University of Calgary, said during hisRead More

Share on facebook
Share on twitter
Share on linkedin